PAVBLU 2 MG / 0.05 ML
AFLIBERCEPT : 2 MG / 0.05 ML · DIN 02550628 · AMGEN CANADA INC
Health Canada status: APPROVED
What is PAVBLU?
PAVBLU 2 MG / 0.05 ML contains AFLIBERCEPT : 2 MG / 0.05 ML. It is listed in the Health Canada Drug Product Database under DIN 02550628, held by AMGEN CANADA INC, supplied as SOLUTION for INTRAVITREAL administration. Health Canada currently lists it as approved, status dated 08-Jul-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02550628 |
|---|---|
| Brand name | PAVBLU |
| Generic / active ingredient | AFLIBERCEPT : 2 MG / 0.05 ML |
| Manufacturer | AMGEN CANADA INC |
| Strength | 2 MG / 0.05 ML |
| Dosage form | SOLUTION |
| Route of administration | INTRAVITREAL |
| Schedule | Schedule D |
| ATC code | S01LA05 AFLIBERCEPT |
| Biosimilar | Yes |
| Health Canada status | APPROVED |
| Status date | 08-Jul-2025 |
What can be used instead?
Other Canadian products sharing ATC code S01LA05 AFLIBERCEPT. 9 of 10 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AFLIVU | 2 MG / 0.05 ML | SOLUTION | APOTEX INC | MARKETED | DIN 02554194 |
| AFLIVU | 2 MG / 0.05 ML | SOLUTION | APOTEX INC | MARKETED | DIN 02554178 |
| EYLEA | 2 MG / 0.05 ML | SOLUTION | BAYER INC | MARKETED | DIN 02505355 |
| EYLEA | 2 MG / 0.05 ML | SOLUTION | BAYER INC | MARKETED | DIN 02415992 |
| EYLEA HD | 8 MG / 0.07 ML | SOLUTION | BAYER INC | MARKETED | DIN 02554798 |
| EYLEA HD | 8 MG / 0.07 ML | SOLUTION | BAYER INC | MARKETED | DIN 02545004 |
| PAVBLU | 2 MG / 0.05 ML | SOLUTION | AMGEN CANADA INC | MARKETED | DIN 02550636 |
| YESAFILI | 2 MG / 0.05 ML | SOLUTION | BIOSIMILAR COLLABORATIONS IRELAND LIMITED | MARKETED | DIN 02535858 |
| YESAFILI | 2 MG / 0.05 ML | SOLUTION | BIOSIMILAR COLLABORATIONS IRELAND LIMITED | MARKETED | DIN 02558238 |
Who else supplies AFLIBERCEPT worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. AFLIBERCEPT appears in 88 registered pack listings across 10 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.